Drug intelligence / Profile preview

FG-3180

Development stage: Phase 1
Lead developer: FibroGen
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

FG-3180 is a CD46-targeted positron emission tomography (PET) imaging agent developed for the diagnosis of solid tumors. It is composed of a radiolabeled antibody targeting CD46, enabling enhanced PET imaging to detect and assess tumors expressing this antigen. The drug is intended as a diagnostic radiopharmaceutical to aid in patient selection and monitoring in oncology, particularly prostate cancer. It is being developed by Fortis Therapeutics and FibroGen. The mechanism of action involves enhancing PET imaging through specific binding to CD46 on tumor cells.

Other names: 89Zr-DFO-YS5FG-3180FG3180FG 3180

Targets

CD46 (CD46 Molecule)

Beyond the preview

Go deeper on FG-3180.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FG-3180.

Explore the full profile